FIGHT-203 Trial: Rates of complete clinical and cytogenetic response with pemigatinib. Responses to pemigatinib were adjudicated by local investigators and according to a central review committee. Central FISH was given priority over local cytogenetic results during CRC adjudications. ^aIn the 2 patients with treated MLN with no morphologic evidence of disease but persistent cytogenetic abnormality, cytogenetic responses were adjudicated, but clinical responses were not.